BOULDER, Colo.--Ribozyme Pharmaceuticals here has developed a new ribozyme-based drug with a little help from its growing bioinformatics department. "We used bioinformatics to identify the drug," explained James McSwiggen, who heads the company's three-person bioinformatics department.
The department expanded over the past year to handle increased business from new collaborative efforts.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
